Coronary StenosisNCT03702764
Coronary Plaque Geometry and Acute Coronary Syndromes
An observational study of Coronary Stenosis and Acute Coronary Syndrome, run by Cardio Med Medical Center at 1 site in Romania.
Trial summary
The aim of GEOMETRY study is to investigate the correlation between coronary plaque geometric modifications and lesion vulnerability in patients with suspected coronary artery disease referred for cardiac computed tomography angiography (CCTA). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction
- What is being tested?
- CCTA
- How many people
- 1,000 participants
- Where
- 1 siteRomania
- Study dates
- 1 Feb 2019to 30 Nov 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Study population includes patients from a single center with suspected coronary artery disease, meeting inclusion and exclusion criteria and undergoing CCTA by physician referral for coronary luminal evaluation.
Who may be able to join
- Patients with suspected coronary artery disease (CAD) and pre-test probability of CAD between 15% and 85%, who undergo CCTA, and in whom CCTA has identified presence of at least one coronary plaque
- Ability to provide informed consent
- Age grater then 18 years
Who cannot join
- Patients with pre-test probability of CAD >85% or <15%
- Electrocardiographic evidence of STEMI
- Presence of pre-existing CAD including prior myocardial infarction
- History of coronary artery revascularization (by percutaneous coronary intervention, stent or bypass graft surgery)
- Atrial fibrillation or other irregular rhythm
- Unwillingness or incapacity to provide informed consent
Show all 13Show fewer
- Allergy to iodine contrast media
- Inability to tolerate beta-blocker medication
- Renal insufficiency (creatinine greater than 1.5 mg/dL) or renal failure requiring dialysis
- Pregnant women or lactation
- Active malignancy or malignancy within the last 5 year prior to enrolment
- Conditions associated with an estimated life expectancy of under 2 years
- Coronary calcium score >1000
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Definition: Impact of Coronary Plaque Geometry on Plaque Vulnerability and Their Association With the Risk of Future Cardiovascular Events in Patients With Chest Pain Undergoing Coronary Computed Tomographic Angiography - the GEOMETRY STUDY
The aim of GEOMETRY study is to investigate the correlation between coronary plaque geometric modifications and lesion vulnerability in patients with suspected coronary artery disease referred for cardiac computed tomography angiography (CCTA). Furthermore the study will evaluate the impact of plaque eccentricity and morphology on the rate of major adverse cardiovascular events (MACE) for a 2 years follow-up period.
Read the detailed description
Coronary artery disease (CAD) remains the leading cause of mortality and morbidity worldwide. Early detection of CAD may reduce the incidence of myocardial infarction by improving primary prevention and providing more effective treatment methods. A step in this direction is identifying the pattern of coronary plaques which are prone to rupture. Coronary computed tomography angiography (CCTA) has emerged recently as a reliable noninvasive tool used in the evaluation of coronary arteries. Some features related to plaque composition and morphology such as low attenuation plaques, spotty calcification, positive remodeling or napkin ring sign, were already identified as vulnerability markers. However the role of lesion geometry on plaque vulnerability was not investigated yet.
This is a prospective, cohort, single-center study which will be carried out in the Center of Advanced Research in Multimodal Cardiac Imaging Cardiomed.
The study will include 1.000 subjects with suspected CAD who are referred to CCTA by the attending physician and in which presence of at least one coronary plaque is confirmed by CCTA.
Plaque burden, composition, and morphology will be assessed for each plaque. Longitudinal and transversal eccentricity will be also assessed in each plaque and in all cases, eccentricity index will be calculated in cross-section plane at the degree of maximum stenosis in order to determine the position of the remaining circulant lumen and to classify the plaque into concentric and eccentric lesion.
The study will be conducted over a period of 3 years, in which patients will be examined at baseline, and will be followed-up for 2 years for occurrence of MACE.
Study objectives:
Primary: to evaluate the association between different patterns of plaque geometry and the risk for major adverse cardiac events MACE (all-cause mortality, cardiovascular death, myocardial infarction, repeated revascularization, repeated hospitalizations for cardiovascular related incidents, cerebrovascular events) during a 2-year follow-up, Secondary: to evaluate the association of plaque eccentricity, plaque vulnerability and plaque progression after 2 years of follow-up
Study Timeline:
- Baseline (day 0)
- Obtain and document consent from participant on study consent form.
- Verify inclusion/exclusion criteria.
- Obtain demographic information, medical history, medication history, alcohol and tobacco use history.
- Record results of physical examinations and 12-lead ECG.
- Collect blood specimens.
- Imaging: 128-multislice CT angiography.
- Visit 1 (month 6)
- Record results of physical examinations, 12-lead ECG and medical history.
- MACE assessment
- Visit 2 (month 12)
- Record results of physical examinations, 12-lead ECG and medical history.
- MACE assessment
- Visit 3 (month 18)
- Record results of physical examinations, 12-lead ECG and medical history.
- MACE assessment
- Final study visit (month 24)
- Record results of physical examinations, 12-lead ECG and medical history.
- Repeat CCTA and plaque assessment
- End-point evaluation.
Study procedures:
- Medical history, clinical examination, laboratory tests;
- 12-lead ECG
- 128-multislice CT coronary angiography with the evaluation of: calcium score, plaque burden, markers for lesion severity (degree of stenosis, lesion length, lumen area and diameter, minimum and maximum plaque thickness); morphological plaque characteristics (plaque related volumes, plaque burden, remodeling indexes); shear stress by computational fluid dynamics; markers of plaque vulnerability (low attenuation plaque, spotty calcification, positive remodeling, napkin ring sign); plaque geometry by eccentricity index, longitudinal and transversal eccentricity.
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atherosclerosis, Atheromatous Plaques
- Being tested
- CCTA
- Keywords
- coronary plaque eccentricity, vulnerable coronary plaque, coronary artery disease, myocardial infarction, coronary computed tomography angiography, major adverse cardiac events
- Medical subject headings
- Coronary Stenosis, Acute Coronary Syndrome, Atherosclerosis, Plaque, Atherosclerotic, Coronary Artery Disease, Myocardial Infarction, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CCTADiagnostic test
128-multislice CT coronary angiography and complex atherosclerotic plaque analysis, with the use of CT imaging post-processing techniques.
| Study group | Role | What they receive |
|---|---|---|
| VP-SG 01 | Study subjects that present concentric coronary plaques Receives: Diagnostic Test: CCTA | |
| VP-SG 02 | Study subjects that present eccentric coronary plaques Receives: Diagnostic Test: CCTA |
What is being measured
The primary outcome is the main question the study is designed to answer.
Major adverse cardiovascular events
Incidence of MACE during follow-up
Measured: Month 24
Secondary outcomes (1)
Coronary plaque vulnerability associated to plaque eccentricity
Number of vulnerability markers in eccentric vs concentric plaques
Measured: Month 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Oct 2018
- Study start1 Feb 2019
- Primary completion30 Nov 2019
- Study completion30 Nov 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary StenosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cardio Med Medical Center
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- University of Targu Mures, Romania, University Hospital of Targu Mures, Romania
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03702764
- Sponsor's protocol ID
- CM0218-GEO
- Status last verified
- Jul 2021
- First submitted
- 8 Oct 2018
- Last updated
- 2 Aug 2022
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Aug 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Definition: Impact of Coronary Plaque Geometry on Plaque Vulnerability and Their Association With the Risk of Future Cardiovascular Events in Patients With Chest Pain Undergoing Coronary Computed Tomographic Angiography - the GEOMETRY STUDY
- ClinicalTrials.gov ID
- NCT03702764
- Acronym / sponsor ID
- CM0218-GEO
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atherosclerosis, Atheromatous Plaques
- Keywords
- coronary plaque eccentricity, vulnerable coronary plaque, coronary artery disease, myocardial infarction, coronary computed tomography angiography, major adverse cardiac events
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,000 participants (actual)
- Lead sponsor
- Cardio Med Medical CenterIndustry (pharma, biotech, devices)
- Collaborators
- University of Targu Mures, Romania, University Hospital of Targu Mures, Romania
- Study start
- 1 Feb 2019 (actual)
- Primary completion
- 30 Nov 2019 (actual)
- Study completion
- 30 Nov 2021 (actual)
- First posted
- 11 Oct 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of GEOMETRY study is to investigate the correlation between coronary plaque geometric modifications and lesion vulnerability in patients with suspected coronary artery disease referred for cardiac computed tomography angiography (CCTA). Furthermore the study will evaluate the impact of plaque eccentricity and morphology on the rate of major adverse cardiovascular events (MACE) for a 2 years follow-up period.
Detailed description
Coronary artery disease (CAD) remains the leading cause of mortality and morbidity worldwide. Early detection of CAD may reduce the incidence of myocardial infarction by improving primary prevention and providing more effective treatment methods. A step in this direction is identifying the pattern of coronary plaques which are prone to rupture. Coronary computed tomography angiography (CCTA) has emerged recently as a reliable noninvasive tool used in the evaluation of coronary arteries. Some features related to plaque composition and morphology such as low attenuation plaques, spotty calcification, positive remodeling or napkin ring sign, were already identified as vulnerability markers. However the role of lesion geometry on plaque vulnerability was not investigated yet.
This is a prospective, cohort, single-center study which will be carried out in the Center of Advanced Research in Multimodal Cardiac Imaging Cardiomed.
The study will include 1.000 subjects with suspected CAD who are referred to CCTA by the attending physician and in which presence of at least one coronary plaque is confirmed by CCTA.
Plaque burden, composition, and morphology will be assessed for each plaque. Longitudinal and transversal eccentricity will be also assessed in each plaque and in all cases, eccentricity index will be calculated in cross-section plane at the degree of maximum stenosis in order to determine the position of the remaining circulant lumen and to classify the plaque into concentric and eccentric lesion.
The study will be conducted over a period of 3 years, in which patients will be examined at baseline, and will be followed-up for 2 years for occurrence of MACE.
Study objectives:
Primary: to evaluate the association between different patterns of plaque geometry and the risk for major adverse cardiac events MACE (all-cause mortality, cardiovascular death, myocardial infarction, repeated revascularization, repeated hospitalizations for cardiovascular related incidents, cerebrovascular events) during a 2-year follow-up, Secondary: to evaluate the association of plaque eccentricity, plaque vulnerability and plaque progression after 2 years of follow-up
Study Timeline:
- Baseline (day 0)
- Obtain and document consent from participant on study consent form.
- Verify inclusion/exclusion criteria.
- Obtain demographic information, medical history, medication history, alcohol and tobacco use history.
- Record results of physical examinations and 12-lead ECG.
- Collect blood specimens.
- Imaging: 128-multislice CT angiography.
- Visit 1 (month 6)
- Record results of physical examinations, 12-lead ECG and medical history.
- MACE assessment
- Visit 2 (month 12)
- Record results of physical examinations, 12-lead ECG and medical history.
- MACE assessment
- Visit 3 (month 18)
- Record results of physical examinations, 12-lead ECG and medical history.
- MACE assessment
- Final study visit (month 24)
- Record results of physical examinations, 12-lead ECG and medical history.
- Repeat CCTA and plaque assessment
- End-point evaluation.
Study procedures:
- Medical history, clinical examination, laboratory tests;
- 12-lead ECG
- 128-multislice CT coronary angiography with the evaluation of: calcium score, plaque burden, markers for lesion severity (degree of stenosis, lesion length, lumen area and diameter, minimum and maximum plaque thickness); morphological plaque characteristics (plaque related volumes, plaque burden, remodeling indexes); shear stress by computational fluid dynamics; markers of plaque vulnerability (low attenuation plaque, spotty calcification, positive remodeling, napkin ring sign); plaque geometry by eccentricity index, longitudinal and transversal eccentricity.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| VP-SG 01 | – | Diagnostic Test: CCTAStudy subjects that present concentric coronary plaques |
| VP-SG 02 | – | Diagnostic Test: CCTAStudy subjects that present eccentric coronary plaques |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Study population includes patients from a single center with suspected coronary artery disease, meeting inclusion and exclusion criteria and undergoing CCTA by physician referral for coronary luminal evaluation.
Key inclusion criteria (3 listed)
- Patients with suspected coronary artery disease (CAD) and pre-test probability of CAD between 15% and 85%, who undergo CCTA, and in whom CCTA has identified presence of at least one coronary plaque
- Ability to provide informed consent
- Age grater then 18 years
Key exclusion criteria (13 listed)
- Patients with pre-test probability of CAD >85% or <15%
- Electrocardiographic evidence of STEMI
- Presence of pre-existing CAD including prior myocardial infarction
- History of coronary artery revascularization (by percutaneous coronary intervention, stent or bypass graft surgery)
- Atrial fibrillation or other irregular rhythm
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CCTA128-multislice CT coronary angiography and complex atherosclerotic plaque analysis, with the use of CT imaging post-processing techniques. | Diagnostic test | VP-SG 01, VP-SG 02 |
Primary outcome
Major adverse cardiovascular events
Time frame: Month 24
Incidence of MACE during follow-up
1 secondary outcome
Coronary plaque vulnerability associated to plaque eccentricity
Time frame: Month 24
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Aug 2022.
Related trials for Coronary Stenosis
Active, not recruiting
Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable CoreValve Evolut R or Evolut PRO System for the Treatment of Small, Severely Dysfunctional Surgical Aortic Bioprotheses. The 'LYTEN' Trial
Aortic Valve Stenosis, Regurgitation, Aortic
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
Recruiting
Exercise and Diet Supplements for Older Patients Undergoing TAVI: the IRON-TAVI Trial
Aortic Stenosis Disease, Aortic Stenosis Symptomatic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Stenosis and Acute Coronary Syndrome, run by Cardio Med Medical Center at 1 site in Romania.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Romania. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Major adverse cardiovascular events (time frame: Month 24). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Aug 2022.